Type 2 diabetes is a chronic metabolic disease characterized by high blood glucose that results from a combination of insulin resistance and progressive failure of insulin producing beta cells in the pancreas. Research shows that it develops through a long silent phase where blood sugar is only mildly elevated but damage to blood vessels, nerves and organs is already beginning.

Genetic susceptibility influences risk, but rapid lifestyle changes have driven the global rise. Diets rich in refined carbohydrates, added sugars and saturated fats, combined with physical inactivity and excess body weight, especially abdominal fat, strongly increase risk. Fat accumulation in the liver and muscle interferes with insulin signaling, while chronic low grade inflammation further impairs metabolic control.

Studies highlight that early detection and intervention are crucial. Lifestyle interventions that combine weight loss, regular physical activity and healthier eating patterns can prevent or significantly delay progression from prediabetes to type 2 diabetes. Structured programs often achieve sustained improvements in blood sugar, blood pressure and lipids.

Once diabetes is established, research emphasizes individualized treatment. Metformin remains a first line drug that improves insulin sensitivity and reduces liver glucose production. Newer drug classes target different mechanisms. Some enhance insulin secretion in a glucose dependent way, others increase urinary glucose loss or mimic gut hormones to improve satiety, slow gastric emptying and support weight loss. These newer agents have also been shown to reduce cardiovascular and kidney complications in high risk patients.

Overall, the research underscores that type 2 diabetes is largely preventable, that early aggressive management improves long term outcomes, and that modern therapies can address both blood sugar and serious complications.